InvestSMART

PainChek Ltd (ASX: PCK) - Announcements

Current share price for PCK : $0.067 0.011 (14.10%)+

ASX company news and announcements for PainChek Ltd (PCK) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PainChek Ltd (PCK) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PainChek Ltd (PCK), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PainChek Ltd (PCK)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$14 Notification regarding unquoted securities - PCK 19 Dec 2024 10:59AM $0.026 $0.067 risen by 157.69%
$14 Application for quotation of securities - PCK 19 Dec 2024 10:58AM $0.026 $0.067 risen by 157.69%
$14 PainChek completes Entitlement Offer raising AUD $5.1 m 16 Dec 2024 11:39AM $0.026 $0.067 risen by 157.69%
$14 PainChek Implementations, Market and International Expansion 11 Dec 2024 8:21AM $0.027 $0.067 risen by 148.15%
$14 PainChek Entitlement Offer Open 2 Dec 2024 9:58AM $0.028 $0.067 risen by 139.29%
$14 Results of Meeting 28 Nov 2024 6:02PM $0.028 $0.067 risen by 139.29%
$14 PCK AGM watching the live feed 27 Nov 2024 2:11PM $0.027 $0.067 risen by 148.15%
$14 Proposed issue of securities - PCK 25 Nov 2024 9:52AM $0.028 $0.067 risen by 139.29%
$14 Prospectus 25 Nov 2024 9:52AM $0.028 $0.067 risen by 139.29%
$14 Underwritten Entitlement Offer to raise AUD $5.1million 25 Nov 2024 9:51AM $0.028 $0.067 risen by 139.29%
$14 Trading Halt 21 Nov 2024 9:10AM $0.028 $0.067 risen by 139.29%
$14 PCK submits application for Adult App FDA De Novo clearance 20 Nov 2024 8:21AM $0.028 $0.067 risen by 139.29%
$14 Addendum to BESTMED reseller agreement announcement 19 Nov 2024 10:31AM $0.029 $0.067 risen by 131.03%
$14 PCK expands market reach with BESTMED reseller agreement 13 Nov 2024 8:44AM $0.028 $0.067 risen by 139.29%
$14 Quarterly Investor Presentation 30 Oct 2024 8:29AM $0.034 $0.067 risen by 97.06%
$14 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2024 8:27AM $0.034 $0.067 risen by 97.06%
$14 Positive study results pave way for PainChek FDA submission 29 Oct 2024 9:06AM $0.028 $0.067 risen by 139.29%
$14 Appendix 4C quarterly webinar - 11am AEDT 30 October 2024 28 Oct 2024 8:43AM $0.029 $0.067 risen by 131.03%
$14 Notice of Annual General Meeting/Proxy Form 25 Oct 2024 10:54AM $0.027 $0.067 risen by 148.15%
$14 Change of Director's Interest Notice 4 Oct 2024 2:25PM $0.030 $0.067 risen by 123.33%
$14 Notification of cessation of securities - PCK 4 Oct 2024 2:14PM $0.030 $0.067 risen by 123.33%
$14 Application for quotation of securities - PCK 2 Oct 2024 9:26AM $0.030 $0.067 risen by 123.33%
$14 PainChek Adult app FDA De Novo submission update 2 Oct 2024 9:11AM $0.030 $0.067 risen by 123.33%
$14 Corporate Governance Statement & Appendix 4G 2024 30 Sep 2024 8:26AM $0.030 $0.067 risen by 123.33%
$14 Annual Report to shareholders 30 Sep 2024 8:25AM $0.030 $0.067 risen by 123.33%

126 - 150 of 486 results

Page 6 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.